Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I by Xiangyi Kong, Ryan J Sullivan, Caisheng Wu, Lin Zhang, Lin Zhang, Lin Zhang, Yu Jiang

Connect to this object online.

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II by Chuqi Lei, Xiangyi Kong, Xiangyi Kong, Ryan J. Sullivan, Caisheng Wu, Caisheng Wu, Dawei Wang, Lin Zhang, Lin Zhang, Lin Zhang

Connect to this object online.

The impact of stage-related features in melanoma recurrence prediction: A machine learning approach by Guihong Wan, PhD, Bonnie Leung, BS, Nga Nguyen, MD, MPH, Mia S. DeSimone, MD, MPH, Feng Liu, PhD, Min Seok Choi, MS, Diane Ho, RHIA, CTR, Valerie Laucks, BS, Stacey Duey, MCPH, Ryan J. Sullivan, MD, Genevieve M. Boland, MD, PhD, Nicole R. LeBoeuf, MD, MPH, David Liu, MD, MPH, Alexander Gusev, PhD, Shawn G. Kwatra, MD, Peter K. Sorger, PhD, Kun-Hsing Yu, MD, PhD, Yevgeniy R. Semenov, MD, MA

Connect to this object online.

Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyCapsule Summary by Xue Bai, MD, Aleigha R. Lawless, BS, Juliane A. Czapla, MS, Stefanie C. Gerstberger, MD, PhD, Benjamin C. Park, MD, Seungyeon Jung, BA, Rebecca Johnson, MN, Naoya Yamazaki, MD, PhD, Dai Ogata, MD, PhD, Yoshiyasu Umeda, MD, Caili Li, MB, Jun Guo, MD, PhD, Keith T. Flaherty, MD, Yasuhiro Nakamura, MD, PhD, Kenjiro Namikawa, MD, PhD, Georgina V. Long, MBBS, PhD, Alexander M. Menzies, MBBS, PhD, Douglas B. Johnson, MD, Ryan J. Sullivan, MD, Genevieve M. Boland, MD, PhD, Lu Si, MD

Connect to this object online.